Matt dives into a specific healthcare topic to help those in the industry, and those outside of it, better understand the market drivers causing today’s healthcare challenges.

Congress wrote 340B into law to help hospitals stretch scarce dollars for vulnerable patients. In 2024 the program moved 82 billion dollars in discounted drugs. Almost none of that money carries proof it reached a single patient. A program built on a promise now runs on faith. That should bother everyone who claims to defend patients, because a discount nobody can trace is not advocacy. It is accounting nobody wants to open.

I have circled patient advocacy long enough to watch 340B grow from a line item almost nobody could explain into the second largest drug purchasing program in the country. Four separate 340B stories hit my desk in a single week. The program has momentum, lawyers, and talking points. What it does not have is a receipt.

Start with the growth. A Tufts analysis by Brian Reid and Peter Neumann at the Center for the Evaluation of Value and Risk in Health tracks 340B sales climbing from 9 billion dollars a decade ago to 82 billion in 2024, using HRSA’s own purchase data. The same analysis points to a 2024 IQVIA finding that the program drains more than 5 billion dollars in commercial rebates in a single year, money that would otherwise hold down premiums for employers and their workers.

Now sit that next to who holds the money. A Health Affairs Scholar study that drew on 2023 Medicare Cost Reports found that 340B hospitals carried 47.5 percent greater total assets than structurally similar hospitals outside the program. Those same hospitals spent 22.8 percent more on administrative salaries, roughly 7 million dollars more per hospital every year. Leaders sell 340B on patient need. The money runs through institutions that keep getting richer, and the salary line grows faster than the charity line.

Here is where the advocacy lens earns its keep. When ELAVAY and the BIOADVOCATE Benchmark measure how patient advocacy organizations judge their corporate partners, one theme separates the trusted from the distrusted every time. Advocates reward partners who can trace intent to outcome, and they walk away from the ones who cannot. 340B fails that test at 82 billion dollars in scale.

The failure has a structure, and the structure has names.

Disproportionate Share Hospitals face no requirement to report how they spend 340B revenue. So a system can pour the margin into administrative growth and acquisitions while charity care stays flat, and no rule forces the disclosure that would prove otherwise.

HRSA stewards the program and has never built the claims-level reporting that would settle the argument in an afternoon. The agency runs an 82 billion dollar channel without the one data feed that would show where the money lands.

Hospital trade groups defend the fog as a feature. The American Hospital Association, now handing the reins to incoming CEO Steve Walsh this fall, has spent years framing transparency as an attack rather than a standard.

Manufacturers fund the duplicate discounts and pass the cost forward, where it lands on employers and state Medicaid programs as higher premiums and lost rebates. Everyone in the chain has a reason to keep the scoreboard dark. That is the tell.

You ghost your own socials by Wednesday. SureThing learns your voice and ships native posts to LinkedIn, X, Instagram, and TikTok, without you writing a thing.

Post in Your Voice

The organizations that keep public trust do the opposite of hide. In ELAVAY, the companies that top the transparency scores show how their patient investments convert to patient outcomes, and they pull advocacy partners into the measurement instead of keeping them at arm’s length. Trust follows proof. It always has.

The reform on the table asks for very little. The Tufts authors lay out three moves. Flag 340B claims at the claims level so duplicate discounts surface before the money moves. Give independent researchers access to the channel data so anyone without a stake in the answer can study the program. Require providers to report how they actually use 340B funds. A hospital confident its 340B revenue serves patients loses nothing by proving it. The ones fighting the receipts tell you exactly what they fear.

If you lead an advocacy function, stop letting 340B hide behind its mission statement and start demanding the receipts. The credibility of every patient-benefit claim in healthcare takes a hit when a program this large runs unaudited, and your organization’s claims sit in the same room.

If you lead a commercial or market access team, model your rebate exposure now and bring your advocacy partners into that analysis rather than briefing them after the fact. The next 340B rule will move whether you prepared for it or not.

Archo built ELAVAY and the BIOADVOCATE Benchmark to measure this exact gap between stated intent and proven outcome. If you want to see where your organization stands before the next rule drops, email [email protected].